Загрузка...
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population
BACKGROUND. Nivolumab has shown a survival benefit compared with docetaxel as second‐line treatment for patients with previously treated advanced squamous non‐small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients and physicians in routine clinical practice are o...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6853127/ https://ncbi.nlm.nih.gov/pubmed/30996007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0737 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|